Fios welcomes a new Head of Commercial Operations

We’re really pleased to announce that Michael Reynolds has joined Fios Genomics as Head of Commercial Operations.

Michael has over 20 years of experience in working for major pharmaceutical companies or selling to life science organisations. With a an extensive experience in sales and general management and knowledge of the pharmaceutical industry, he offers a deep understanding of Genomic, Drug Safety and Quality spaces.

The rapid growth of our business in the international market identified for Fios Genomics the need for a Head of Commercial Operations to meet the business demand. Last year, our team’s efforts have been recognised in a publication in Nature, showcasing our capabilities to the global network.

“We’re proud to welcome Michael to our team,” said Sarah Lynagh, CEO at Fios Genomics.  “He brings a solid record of successful leadership experience to our team.”

Michael is very enthusiastic to work with Fios Genomics and says:

“ I am delighted to join Fios Genomics as they continue to grow. Over the last 6 years, Fios Genomics have made significant strides in building their expertise and offering, to enable them to help companies discover the biology in their data. Growing the company on the back of conclusions that are data-driven and led by biology rather than statistics is exciting for the whole of the team here at Fios.“

About Fios Genomics

Fios Genomics is a bioinformatics service provider performing data-analysis, -mining and -integration projects for companies and research institutions worldwide. We are currently in a period of sustained and rapid growth and are looking for talented and ambitious individuals to join our sales team.

Fios Genomics provides an extensive range of genomic and bioinformatic data analysis services to Pharma, CROs and academia for drug discovery & development and applied research. These services provide expert statistical and pathway-based approaches for the analysis and interpretation of a variety of data types generated from R&D, pre-clinical development and clinical validation for applications ranging from biomarker & pathway discovery, predictive toxicology, pharmacogenomics and pharmacogenetics (SNP genotyping/ DNA sequencing).

We have extensive expertise in therapeutic areas such as immunology, inflammation, oncology and infectious diseases which can be applied to the analysis, mining and interpretation of data for discovery of genomic (RNA and DNA) biomarkers and biological pathways. Fios can also perform meta-analyses of data from multiple sources.